Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.61 |
| ▸ | CTSD | P07339 | 7/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464647 | 1.00 | BACE1 (0.61) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL429076 | 0.78 | BACE1 (0.77) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL431081 | 0.78 | BACE1 (0.77) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL427974 | 0.76 | BACE1 (1.00) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL9931676 | 0.70 | BACE1 (0.57) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL9931677 | 0.70 | BACE1 (0.57) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL428052 | 0.68 | BACE1 (0.64) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL8531555 | 0.68 | BACE1 (0.55) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL14052997 | 0.67 | BACE1 (0.60) | BACE1CTSDKCNH2CYP2D6 | |
| SCHEMBL14052998 | 0.67 | BACE1 (0.60) | BACE1CTSDKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885CTSD 427/4885KCNH2 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.